Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine.

Amylin (AMY3) antagonist (IC50 = 0.3 μM). Protects neuronal cells from Aβ(1-42)-induced cytotoxicity in vitro. Brain penetrant. Improves spatial memory and reduces Aβ plaque number and total area in a mouse Alzheimer's disease model.

5A2-SC8 is an ester-based dendrimer that acts as a degradable, lipid-like compound for the delivery of small RNAs.